Opendoor Technologies Inc vs Sana Biotechnology Inc — how do they compare? Opendoor Technologies Inc trades at $4.36 (market cap $4.32B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Opendoor Technologies Inc is far larger — about 4.9× Sana Biotechnology Inc's market cap, and Opendoor Technologies Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| OPEN | SANA | |
|---|---|---|
Market Cap | $4.32B | $879.40M |
Sector | Real Estate | Health |
52-Week High | $10.52 | $5.92 |
52-Week Low | $1.84 | $2.68 |
Enterprise Value | $4.66B | $853.59M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Trailing returns across standard periods
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →